ETRA insider filings
Electra Therapeutics, Inc. — 11 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-10. Screen ETRA transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 11 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 36 legs across 6 filings by 4 insiders — 3,796,040 shares, $48,699,284 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: purchase of 1,000,000 shares @ $15.00 ($15,000,000) by GORDON CARL L, filed 2026-09-23.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| GORDON CARL L — Director, 10% owner | 3 | 18 legs · 1,898,020 sh · $24,349,642 | — | 8 |
| ORBIMED ADVISORS LLC — Director, 10% owner & OrbiMed Capital GP VII LLC — Director, 10% owner & OrbiMed Genesis GP LLC — Director, 10% owner | 3 | 18 legs · 1,898,020 sh · $24,349,642 | — | 8 |
| Dong Quehuong (Kathy) — President & CEO, Director | 1 | — | — | 2 |
| Koe Gary S. — Chief Technical Officer | 1 | — | — | 2 |
| Parry Graham — Chief Scientific Officer | 1 | — | — | 2 |
| Stagliano Nancy — Director | 1 | — | — | 2 |
| Westlake BioPartners Fund I, L.P. — 10% owner & Westlake BioPartners GP I, LLC — 10% owner & Westlake BioPartners Fund II, L.P. — 10% owner & Westlake BioPartners GP II, LLC — 10% owner | 1 | — | — | — |
Recent insider filings — Electra Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 4 | GORDON CARL L — Director, 10% owner | Purchase (P): 9,816 @ $7.85 · Purchase (P): 39,600 @ $7.85 · Purchase (P): 4,000 @ $8.24 · Purchase (P): 16,000 @ $8.24 · Purchase (P): 20,700 @ $8.45 · Purchase (P): 2,000 @ $8.45 | EDGAR |
| 2026-11-10 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Purchase (P): 9,816 @ $7.85 · Purchase (P): 39,600 @ $7.85 · Purchase (P): 4,000 @ $8.24 · Purchase (P): 16,000 @ $8.24 · Purchase (P): 20,700 @ $8.45 · Purchase (P): 2,000 @ $8.45 | EDGAR |
| 2026-11-05 | 4 | GORDON CARL L — Director, 10% owner | Purchase (P): 24,313 @ $7.84 · Purchase (P): 97,800 @ $7.84 · Purchase (P): 24,400 @ $7.88 · Purchase (P): 98,600 @ $7.88 · Purchase (P): 9,267 @ $7.78 · Purchase (P): 37,100 @ $7.78 · +4 more | EDGAR |
| 2026-11-05 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Purchase (P): 24,313 @ $7.84 · Purchase (P): 97,800 @ $7.84 · Purchase (P): 24,400 @ $7.88 · Purchase (P): 98,600 @ $7.88 · Purchase (P): 9,267 @ $7.78 · Purchase (P): 37,100 @ $7.78 · +4 more | EDGAR |
| 2026-09-23 | 4 | GORDON CARL L — Director, 10% owner | Conversion (C): 2,002,310 · Conversion (C): 1,087,934 · Conversion (C): 1,703,314 · Purchase (P): 333,333 @ $15 · Conversion (C): 758,279 · Purchase (P): 1,000,000 @ $15 · +4 more | EDGAR |
| 2026-09-23 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Conversion (C): 2,002,310 · Conversion (C): 1,087,934 · Conversion (C): 1,703,314 · Purchase (P): 333,333 @ $15 · Conversion (C): 758,279 · Purchase (P): 1,000,000 @ $15 · +4 more | EDGAR |
| 2026-09-21 | 3 | Westlake BioPartners Fund I, L.P. — 10% owner Westlake BioPartners GP I, LLC — 10% owner Westlake BioPartners Fund II, L.P. — 10% owner Westlake BioPartners GP II, LLC — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-09-21 | 4 | Koe Gary S. — Chief Technical Officer | Conversion (C): 63,656 · Conversion (C): 63,656 (derivative) | EDGAR |
| 2026-09-21 | 4 | Stagliano Nancy — Director | Conversion (C): 255,635 · Conversion (C): 255,635 (derivative) | EDGAR |
| 2026-09-21 | 4 | Parry Graham — Chief Scientific Officer | Conversion (C): 85,504 · Conversion (C): 85,504 (derivative) | EDGAR |
| 2026-09-21 | 4 | Dong Quehuong (Kathy) — President & CEO, Director | Conversion (C): 455,484 · Conversion (C): 455,484 (derivative) | EDGAR |
Recent 8-K events — Electra Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-21 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Electra Therapeutics, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-298617 (S-1) — latest: Final prospectus (424B4), filed 2026-09-18
GET https://api.filingpulse.io/v1/insider-trades?ticker=ETRA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs